Does health insurance cover limb lengthening surgery?

Three questions decide every insurance case. None of them depends on the surgeon or the country.

Question 1: Why does the patient want this surgery? Pure stature gain in a person of average height with normal anatomy is cosmetic, and no insurer in any country routinely reimburses it. A documented congenital limb-length discrepancy, a malunion after a fracture, a leg-length difference from a hip replacement, post-polio shortening, or a skeletal dysplasia (achondroplasia, hypochondroplasia, others) is medical, and most insurers will cover it under reconstructive-surgery clauses.

Question 2: Is the indication documented in the medical chart? Insurers do not pay on a verbal complaint. The patient needs measured imaging (CT scanogram or full-length standing radiograph) showing the discrepancy, a diagnostic code from the ICD-10 system (Q72 for congenital reduction defects of the lower limb, M21 for acquired limb deformities, or the relevant trauma sequela code), and a referral pathway through an orthopedic specialist.

Question 3: Has the patient tried non-surgical alternatives? US prior-authorization forms typically require a documented trial of shoe lifts or orthotics for discrepancies under 2 cm before approving surgical lengthening. Above 2 cm, the surgical indication is usually accepted on first request.

Patients sometimes ask whether they can get a cosmetic case reclassified as reconstructive on paper. The honest answer: no. Insurance fraud is criminal in every country we cover, and surgeons who play this game lose licenses, not just reimbursement.

US insurance treats limb lengthening as a covered reconstructive procedure when the indication is recognised and as an excluded cosmetic procedure otherwise. The medical-necessity threshold sits at a measured limb-length discrepancy of approximately 2 cm or greater, a recognised skeletal dysplasia, or a documented trauma sequela.

The CPT codes that appear on the claim: 27466 (femoral lengthening using intramedullary device), 27465 (femoral shortening, included for completeness, used in equalisation strategies), and 27715 (osteoplasty, tibia and fibula, lengthening or shortening). The ICD-10 codes most commonly attached: Q72.0 through Q72.9 for congenital reduction defects of the lower limb, M21.6 for acquired limb deformities, and S82-/S72- coded fractures for trauma sequelae.

Medicare covers reconstructive limb lengthening when medical necessity is documented. Cosmetic indications are statutorily excluded under the 1972 Social Security Act amendments that exclude cosmetic surgery from Medicare benefits.

Medicaid varies state by state. California's Medi-Cal, New York's Medicaid, and Texas's Medicaid all cover reconstructive cases with prior authorization. Cosmetic indications are universally excluded.

Private insurers, Aetna, Cigna, UnitedHealthcare, BlueCross BlueShield, publish individual medical-coverage policies for limb lengthening. They are searchable on each insurer's clinical-policy-bulletin pages. The pattern is consistent: 2 cm discrepancy threshold, prior authorization required, internal-magnetic-nail implants covered, cosmetic indications excluded. Patients seeing the Hospital for Special Surgery (HSS) or the Rubin Institute for Advanced Orthopedics will be told their case is insurance-led, if a reconstructive indication is documented, out-of-pocket may be near zero. If the indication is cosmetic, the cash price applies and runs $75,000–$160,000.

The UK National Health Service (NHS) covers limb lengthening for reconstructive indications and does not cover cosmetic stature gain. The Royal National Orthopaedic Hospital (RNOH) in Stanmore is the NHS national specialist centre, it performs roughly 80–120 NHS-funded limb-reconstruction cases per year, almost all for congenital limb-length discrepancy, post-trauma sequelae, achondroplasia, or post-tumor reconstruction.

The NHS pathway runs through a GP referral to an NHS orthopaedic clinic, then onwards to a specialist limb-reconstruction service if the indication meets the criteria. Waiting times to first consultation vary regionally, typically 12–26 weeks. Patients with measurable discrepancy above 2.5 cm or recognised skeletal dysplasia are accepted; patients with normal anatomy seeking cosmetic gain are not.

Cosmetic patients in the UK pay out of pocket and travel either to private UK clinics (TallTech Clinic in Cheltenham, Orthopaedic Specialists in London, neither publishes a number, expect £45,000–£90,000) or abroad. The single biggest UK-patient destination by volume is Turkey, with India as a second.

UK private-medical-insurance plans (Bupa, AXA, Vitality) follow the NHS line: reconstructive yes, cosmetic no. Some plans will cover the cost of follow-up imaging and physiotherapy after a self-funded surgery abroad if the patient develops a complication that meets the policy's emergency-care provisions, read the policy schedule before you book.

Germany's statutory health insurance (gesetzliche Krankenversicherung, GKV) covers limb lengthening for medical indications under the same reconstructive logic that applies in the UK and US. Techniker Krankenkasse, Barmer, AOK, and DAK each publish their own internal criteria, but all converge on the same rule: a measurable limb-length discrepancy of 2 cm or greater, a recognised dysplasia, or a documented trauma sequela.

Private German insurance (private Krankenversicherung, PKV) provides broader coverage. Some PKV plans will cover reconstructive lengthening with shorter prior-authorization timelines and access to PRECICE 2 / PRECICE Max implants without an explicit cost cap. Cosmetic cases remain excluded.

The three German clinics in our directory, ZEM Germany Limb Lengthening Center (Munich), 3D Surgery / Dr. Peter Thaller (Munich, Berlin, LMU), and Becker Betz Institute (Munich), split their case books between insurance-covered reconstructive work and out-of-pocket cosmetic patients. Reconstructive patients pay the GKV-set fee schedule. Cosmetic patients pay $55,000–$175,000 depending on clinic and method.

German patients with a clear reconstructive indication should expect roughly 4–8 weeks from GP referral to surgical consultation, and another 6–12 weeks from surgical consultation to operation date. The system is slow but predictable. Cosmetic patients receive no coverage and choose between paying the German private rate or flying to Turkey.

France's statutory assurance maladie covers reconstructive limb lengthening at the standard SECU rate when indication and documentation criteria are met. The patient's complementary insurance (mutuelle) typically covers the gap between SECU reimbursement and full hospital billing, which means a French patient with a strong indication and a good mutuelle plan can complete a reconstructive lengthening with near-zero out-of-pocket cost.

Cosmetic indications are excluded, in line with every other EU country. Cosmetic patients in France typically travel to Turkey or to Paley European Institute in Warsaw (which charges $60,000–$95,000 with Paley-trained surgeons).

French reconstructive cases are most often handled in the public hospital network (CHU). There are no large dedicated cosmetic-LL clinics in France, which reflects the country's regulatory stance: the surgery is treated as a reconstructive subspecialty inside academic orthopedics, not as a separate commercial product line.

Public insurance in Turkey (SGK) covers reconstructive limb lengthening for Turkish citizens and residents under the same medical-necessity rules used in EU systems. Foreign patients are out-of-pocket by default and pay the international-patient package rate ($22,000–$50,000 in our 7-clinic Turkish directory).

India's public hospital system (CGHS, ESIC) covers reconstructive cases for citizens. Foreign patients pay the international-patient rate ($7,500–$45,000 across the 4 verified Indian clinics). Some Indian private insurance plans (Star Health, HDFC Ergo) cover reconstructive limb lengthening with sub-limits, patients should read the policy schedule carefully before claiming.

Iran, Egypt, and Russia: domestic insurance arrangements exist for citizens but do not extend to foreign patients. Foreign patients pay cash.

UAE: private insurance plans (Daman, AXA Gulf, Bupa Arabia) provide partial coverage for reconstructive cases at Dubai and Abu Dhabi clinics, including Paley Middle East Clinic at Burjeel Medical City in Abu Dhabi. The cosmetic case continues to be cash-priced. UAE Emirati nationals receive broader coverage through the public-sector schemes than expatriates do.

The clinical line is set by measurement and documentation, not by the patient's stated preference. Three buckets matter.

Reconstructive (universally covered with paperwork):

• Congenital limb-length discrepancy >2 cm with full-length standing radiograph or CT scanogram measurement (ICD-10 Q72.x). • Post-traumatic shortening after a fracture, dislocation, or growth-plate injury, documented with imaging. • Skeletal dysplasia: achondroplasia, hypochondroplasia, multiple epiphyseal dysplasia, others. • Post-infection sequelae: osteomyelitis-related growth arrest. • Post-tumor reconstruction: lengthening after bone-tumor resection. • Hip-replacement leg-length difference (less commonly approved, depends on insurer).

Grey zone (insurer-by-insurer):

• Constitutional short stature without dysplasia: rarely covered, sometimes covered if growth-hormone failure is documented. • Disproportionate short legs (acromelic or rhizomelic patterns) in an otherwise short patient: depends on the specific pattern and the surgeon's documentation. • Limb-length discrepancy of 1–2 cm: shoe lifts mandated first; surgical approval inconsistent.

Cosmetic (not covered anywhere):

• Stature gain in a patient with measured limb-length difference under 1 cm. • Stature gain in a patient at average or above-average height. • Stature gain for aesthetic, professional, or social reasons.

The surgeon writes the indication on the operative note. An insurer auditing the file two years later can downgrade reconstructive to cosmetic if the documentation does not support the original code, and the patient becomes liable for the original cash price.

Six questions, sent in writing, save patients five-figure surprises later.

First: does my policy cover limb lengthening under CPT 27466 (femoral lengthening) and CPT 27715 (tibial lengthening)? Insurers must point to a published medical-coverage policy.

Second: what is the prior-authorization process and what documentation is required? Most US insurers require imaging showing the discrepancy, a referral from an orthopedic specialist, and a documented trial of non-surgical alternatives.

Third: which implant types are covered? PRECICE 2 and PRECICE Max are typically approved; the recalled Stryde nail is not.

Fourth: what is the in-network surgeon list for this procedure? Out-of-network billing is the largest source of unexpected charges; an in-network surgeon at a contracted hospital is the only fully predictable path.

Fifth: what is covered post-operatively? Implant removal at 12–18 months, physiotherapy, follow-up imaging, complication treatment, each can be a separate authorization.

Sixth: what is the patient out-of-pocket maximum for this plan year? On a high-cost surgery, hitting the policy's out-of-pocket max is often the difference between a manageable bill and a financially ruinous one.

Keep every reply in writing. Insurance carriers reverse phone-only approvals when the bill arrives. A written approval on letterhead, with the policy number, the CPT codes, and the in-network provider, is the only one that holds.